11.25.25 -- CRISPR And iPSC Disease Modeling And Drug Screening

Small-scale perfusion-mimic models can effectively predict media performance in continuous bioreactors to help optimize cell density, productivity, and scalability for CHO cell lines.

Investigate how CAR-T cells treat hematopoietic malignancies as well as the correlation between flow cytometry and qPCR in monitoring CAR-T cell therapy, which validates their combined use for accurate assessment.

Explore how chromatography resins are evolving from purification tools to therapeutic agents in cancer treatment, with insights into their chemical properties and clinical potential.

Uncover a scalable, sterile solution for isolating extracellular vesicles (EVs) in exosome therapeutics to enhance yield, purity, and commercial viability through innovative filtration technology.

Through this collection, review how a proven, automated solution can help facilities stay compliant, operational, and protected — whether in a crisis or during planned maintenance.

Manual processes are yielding to automated, GMP-compliant closed systems in CGT manufacturing. This shift is crucial for meeting Annex 1 contamination standards and creating scalable, reliable commercial production.

Cell banking stands at the forefront of medical advancement. This guide delves into the steps involved in protecting these priceless resources, from cell collection and processing to storage and cell expansion.

Delve into advanced magnetic bead-based methods for isolating T cells, enabling high efficiency, scalability, and viability in CAR T cell manufacturing while addressing challenges posed by diverse patient samples.

Conventional electroporation methods struggle with damaging heat buildup. Assimilate how innovative flow technology leverages physics to protect cells and enable large-scale therapeutic production.

Discover how Seattle Children's Therapeutics leveraged tools to develop an efficient in-house lentiviral vector production process to accelerate timelines and enhance productivity through precise, data-driven estimations.

Single-use technology and innovative fluid connections play a significant role in creating an effective, sterile fill and finish operation that maintains the integrity of your biologic products.

An innovative transfection system addresses common production challenges by offering higher AAV titers, improved percent-full AAV capsids, and a straightforward workflow for AAV production platforms.

This article discusses options for cell therapy process development and validation that minimize risks through quality control (QC), optimization, scaling, closing, automation, and assay development.